Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases
Perk Inhibitor HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy in Combination with Anti-PD1 Immune Checkpoint Inhibitor Antibody
Cancer immunotherapy via myeloid signaling pathway co-activation (Wattenberg et al. AACR Pancreatic Cancer 2022)
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells
A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG
Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan
Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)